(Q35982970)

English

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

G Pichert

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

L M Jost

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

W Fierz

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

R A Stahel

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

1 February 1991

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

63

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

287-292

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1991.67

0 references

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Interleukin-2: inception, impact, and implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971775

2 October 2017

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1997108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1991.67

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35982970&oldid=1597034716"